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IMPORTANCE There is an urgent need to identify reliable biomarkers of amyotrophic lateral
sclerosis (ALS) progression for clinical practice and pharmacological trials.
OBJECTIVES To correlate several hematological markers evaluated at diagnosis with ALS
outcome in a population-based series of patients (discovery cohort) and replicate the
findings in an independent validation cohort from an ALS tertiary center.
DESIGN, SETTING, AND PARTICIPANTS The discovery cohort included 712 patients with ALS
from the Piemonte and Valle d’Aosta Register for Amyotrophic Lateral Sclerosis from January
1, 2007, to December 31, 2011. The validation cohort comprised 122 patients with ALS at
different stages of disease consecutively seen at an ALS tertiary center between January 1,
2007, and January 1, 2009.
MAIN OUTCOMES ANDMEASURES The following hematological factors were investigated and
correlated with survival: total leukocytes, neutrophils, lymphocytes, monocytes, glucose,
creatinine, uric acid, albumin, bilirubin, total cholesterol, triglycerides, high-density
lipoprotein cholesterol, low-density lipoprotein cholesterol, creatine kinase,
thyroid-stimulating hormones, and erythrocyte sedimentation rate; all analyses were
performed separately by sex. The patient of the validation cohort also underwent
bioelectrical impedance analysis for the calculation of fat-free mass.
RESULT Of the 712 patients in the examined period in Piemonte and Valle d’Aosta, 638
(89.6%) were included in the study. Only serum albumin (men:4.3 vs >4.3 mg/dL, P < .001;
women:4.3 vs >4.3 mg/dL, P < .001) and creatinine levels (men:0.82 vs >0.82mg/dL,
P = .004; women:0.65 vs >0.05mg/dL, P = .004) and lymphocyte count (men:1700 vs
>1700/μL, P = .04; women:1700 vs >1700/μL, P = .02) were significantly associated with
ALS outcome in both sexes with a dose-response effect (better survival with increasing
levels). These findings were confirmed in the validation cohort. Multivariable analysis showed
that serum albumin (men: hazard ratio [HR], 1.39; 95% CI, 1.05-1.90; P = .02; women: HR,
1.73; 95% CI, 1.35-2.39; P = .001) and creatinine (men: HR, 1.47; 95% CI, 1.11-1.95; P = .007;
women: HR, 1.49; 95% CI, 1.07-2.05; P = .02) were independent predictors of survival in both
sexes; no other hematological factor was retained in themodel. In patients with ALS, serum
albumin was correlated with markers of inflammatory state while serum creatinine was
correlated with fat-free mass, which is a marker of muscle mass.
CONCLUSIONS AND RELEVANCE In ALS, serum albumin and creatinine are independent
markers of outcome in both sexes. Creatinine reflects themuscle waste whereas albumin is
connected with inflammatory state. Both creatinine and albumin are reliable markers of the
severity of clinical status in patients with ALS and can be used in defining prognosis at the
time of diagnosis.
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Amyotrophic lateral sclerosis (ALS) is a neurodegen-erative disorder of adult life characterized by the in-volvement of upper and lower motor neurons and, in
about 50% of patients, prefrontal areas. In most cases, ALS
appears sporadically in the population; roughly 10% of
patients have a positive family history for ALS or frontotem-
poral dementia.1
Amyotrophic lateral sclerosis is almost invariably fatalwith
amediansurvival timeof2 to4years fromonsetand1 to3years
from diagnosis.2 The only drug that has been found to be ef-
fective in prolonging life is riluzole, which increases life ex-
pectancy by about 3 months.3
Several clinical prognostic factors have been identified in
ALS, namely age, site of onset, functional and respiratory sta-
tus, cognitive function, noninvasive ventilation, some ge-
netic mutations,2 and clinical phenotypes.4 In addition, vari-
ous biological markers have been proposed as potentially
related to a better ALS outcome including dyslipidemia,5,6 el-
evated levels ofuric acid7,8 andcreatinine, and reducedgranu-
locyte count.9 However, most of these markers have been
evaluatedonly in small single-center series andhavenot been
confirmed by subsequent studies.
The aim of this studywas to assess the correlation of sev-
eral hematological markers evaluated at diagnosis with ALS
outcome in a population-based series of patients living in the
Piemonte and Valle d’Aosta regions of Italy between January
1, 2007, and December 31, 2011. The study findings were then
replicated in an independent validation cohort from an ALS
tertiary center.
Methods
Discovery Cohort
The study design was approved by the institutional ethical
committees of Azienda Ospedale Università, Città della Sa-
lute e della Scienza, and Azienda Ospedale Università Mag-
giore di Novara. Patients providedwritten informed consent.
All patientswithALS in thePiemonte andValle d’Aosta re-
gions of Italy (n = 712), identified through the Piemonte and
Valle d’Aosta Register for ALS10 and diagnosed between Janu-
ary 1, 2007, and December 31, 2011, were eligible for enroll-
ment in the study. All patients met the revised El Escorial
diagnostic criteria for definite and probable laboratory-
supportedALS.11 A complete clinical historywas collected for
each patient. Disease severity was assessed with the Amyo-
trophicLateral SclerosisFunctionalRatingScale–Revisedscale
(ALSFRS-R).12 Pulmonary function testswereperformedatdi-
agnosis and forced vital capacity (FVC) percentage of predic-
tionwas annotated. Bodymass index (BMI)was calculated as
weight inkilogramsdividedbyheight inmeters squared.2Body
weight was measured with individuals wearing only under-
wear and no shoes by means of a steelyard scale (precision,
±100 g). Body height was measured by means of a stadiom-
eter (precision, ±0.5 cm). Patientswho couldnotmaintain the
erect positionwereweighed in the seatedposition on an elec-
tronic chair scale (Seca)while bodyheightwasdeterminedby
measuring the knee height.13 No differences were found be-
tween thesemethods. Levels of BMIwere categorized accord-
ing to theWorld Health Organization classification.14
In addition, the decline rate for ALSFRS-R score and its 4
subscores (bulbar, finemotor,grossmotor,andrespiratory)was
calculated as the mean monthly number of points lost from
symptomonset to the timeof diagnosis. TheFVCandBMIde-
cline were also calculated.
Patients underwent hematological examinations as part
of the diagnostic workup. Blood sampling was performed af-
ter overnight fasting. The following hematological tests were
considered for this study: total leukocytes, neutrophils, lym-
phocytes, monocytes, glucose, creatinine, uric acid, albu-
min, bilirubin, total cholesterol, triglycerides, high-density li-
poprotein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, creatinekinase, thyrotropin, anderythrocyte sedi-
mentation rate (ESR). Five male patients who had a creati-
nine level in the range from 1.3 to 1.8mg/dL (to convert tomi-
cromoles per liter, multiply by 76.25), indicating a reduction
of renal function, were excluded from the study.
A total of 565 patients also underwent an extensive ge-
neticassessmentusingstandardprocedures.15Thirty-sevenpa-
tients (6.6%) carried aC9ORF72GGGGCC repeat expansion, 17
(3.0%) carriedSOD1missensemutations, 6patients (1.2%) car-
riedTARDBPmissensemutations, 1patient carriedanFUSand
1 patient carried anOPTNmissensemutation, and 16 patients
(2.8%) carried polyQ repeat expansions (≥31) in the ATNX2
gene.
Validation Cohort
Thiscohortconsistedof 122patientswithALSatdifferentstages
of the disease consecutively seen at anALS tertiary center be-
tween 2007 and 2009. Patients underwent all the sameevalu-
ations of the discovery cohort plus fat-free mass (FFM; in ki-
lograms),determinedbybioelectrical impedanceanalysisusing
a single-frequency tetrapolar techniquewith anelectrical cur-
rent of 800 mA at 50 kHz (STA-BIA; Akern) according to a
method validated for ALS.16,17
Statistical Methods
Comparisons between means were made with the t test or
analysis of variance, comparison between categorical vari-
ableswasmadewith the χ2 test, and the equality of variances
was confirmedwith the Levene test. Correlationswere calcu-
latedwith thePearson coefficient; becausemultiple compari-
sons were performed, P values were Bonferroni-adjusted
(Table 1 and Table 2).
Survival was calculated from diagnosis to death, trache-
ostomy, or censoring date (December 31, 2013) using the
Kaplan-Meier method and compared with the log-rank test.
No patient was lost to follow-up. For survival analysis, each
hematological factor was dichotomized according to its me-
dianvalue.Multivariable analysiswasperformedwith theCox
proportional hazards model (stepwise backward) with a re-
tentioncriterionofP < .10.Twoseparatemodelswereused for
menandwomen; thevariables included in themodel are listed
inTable 2.A level ofP < .05wasconsideredsignificant formul-
tivariable analyses. To assess the prognostic performance of
serum albumin, creatinine, and other significant prognostic
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factors,we calculated test specificity, sensitivity, positivepre-
dictive value, andnegative predictive value using 1-yearmor-
tality after diagnosis as reference. Thenumberneeded to treat
was also calculated. All tests were 2-tailed. Statistical analy-
ses were carried out using a version 20.0 statistical package
(SPSS).
Results
Discovery Cohort
Of the 712 patients in the examined period, 638 (89.6%) were
included in the study, 352 men and 286 women. The remain-
ing 74 patients were not included because of incomplete he-
matological data. Patients’ mean (SD) age at onset was 66.3
(10.7) years (range, 25.3-91.5 years) and mean (SD) ALSFRS-R
scorewas 37.4 (7.5; range, 5-47). Patients included andnot in-
cluded in the study did not differ in regards to demographic
or clinical variables (Table 1).
Theresultsofhematologicalanalysesarereported ineTable
1 in the Supplement. The levels of all hematological para-
meters except for lymphocytes and albumin significantly dif-
fered between sexes. All values were normally distributed
within each sex.
Next, we analyzed the influence of hematological factors
on patients’ survival. The overall median survival from diag-
nosisof thewholecohortwas1.7years (interquartile range,0.8-
3.3 years). The results of univariate analyses for each hema-
tological factorare reported ineTable2 in theSupplement.Only
serum albumin and creatinine levels and lymphocyte count
were significantly related to ALS outcome in both sexes
(Figure 1); patients’ survival increasedwithhigher levels of se-
rum albumin and creatinine and higher lymphocyte count.
Among the other hematological factors, higher levels of total
cholesterol and LDL cholesterol in men as well as lower LDL
cholesterol to HDL cholesterol ratio and higher serum thryo-
tropin levels inwomenwere significantly related to longer sur-
vival. To identify a dose-response effect, serum albumin and
creatininewerealsoassessedaccording to their quartiles; both
factors remained highly significant in both sexes, with a bet-
ter survivalwith increasing levels (eFigures 1 and2 andeTable
3 in the Supplement). The presence of genetic mutations did
not modify the results (data not shown).
To evaluate the ability in predicting 1-year mortality, we
calculated thesensitivity, specificity,positivepredictivevalue,
and negative predictive value of serum creatinine and albu-
min, ALSFRS-R score, FVC, and age (eTable 4 in the Supple-
ment). In both sexes, serum albumin showed sensitivity and
specificity similar to FVC, which is the prognostic factor with
higher values, while creatinine had values similar to age and
ALSFRS-R total score.
Multivariable analysis confirmed that albuminandcreati-
nine levels were independent predictors of survival in both
sexes; no other hematological factors were retained in the
model (Table 2). As expected, other strong predictors of out-
come were patients’ age, FVC, ALSFRS-R bulbar score (both
sexes),ALSFRS-R respiratory score (men), andALSFRS-R total
score (women). Similar results were obtained when we in-
cluded the rate of decline of ALSFRS-R score in themultivari-
able analysis instead of its value at the time of diagnosis (data
not shown).
Next, the correlationbetweenhematologic factors andpa-
tients’ clinical status atdiagnosiswasexplored (eTable 5 in the
Supplement). Creatininewas significantly correlatedwith the
ALSFRS-R total score (Figure 2A), its grossmotor, finemotor,
and respiratory subscores in both sexes, and with FVC
(Figure 2B) andBMI, only inmen.A significant correlationwas
foundbetweenalbuminandALSFRS-R total score (Figure 2C),
all ALSFRS-R subscores, and FVC (Figure 2D) in both sexes.
To better clarify mechanisms underlying the prognostic
role of albumin and creatinine,weperformedanother explor-
atory analysis assessing whether they were correlated with
markers of inflammatory state. In both sexes, serumalbumin
levels significantly decreasedwith the increase of total leuko-
cytes, neutrophils, monocytes, and ESRwhile creatinine lev-
els were not influenced by any marker of inflammatory state
(eTable 6 in the Supplement).
Validation Cohort
To confirmour findings,we considered an independent clini-
cal cohort of patients with ALS. This cohort included 122 pa-
tients (54 men, 68 women), with a mean (SD) age at onset of
59.8 (11.0) years (range, 32.7-83.6 years), disease duration of
2.5 (2.1) years (range, 0.5-10.8 years), and ALSFRS-R score of
25.8 (10.0; range, 3-45). Albumin levels were similar in men
(mean [SD], 4.0 mg/dL [0.4 mg/dL]) and women (mean [SD],
4.0 mg/dL [0.3 mg/dL]) (to convert to grams per liter, multi-
ply by 10), while serum creatinine levels were higher in men
(0.67mg/dL [0.21mg/dL]) than inwomen (0.54mg/dL [0.19])
(P<.001).
Table 1. Demographic and Clinical Characteristics of Patients Included vs Not Included in the Study
Characteristic
Patients Included
(n = 638)
Patients Not Included
(n = 74) P Value
Age at onset, mean (SD), y 66.3 (10.7) 66.6 (11.9) .83
Sex, No. (%)
Female 286 (44.8) 36 (48.6) .52
Site of onset, No. (%)
Bulbar 198 (31.0) 30 (40.5) .09
Diagnostic delay, mean (SD), y 0.96 (0.61) 0.91 (0.64) .75
ALSFRS-R score at diagnosis, mean (SD) 37.4 (7.5) 38.3 (9.1) .64
BMI 24.5 (4.3) 24.7 (4.5) .83
Abbreviations: ALSFRS-R,
Amyotrophic Lateral Sclerosis
Functional Rating Scale–Revised; BMI,
bodymass index (calculated as
weight in kilograms divided by height
in meters squared).
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Mean (SD) BMI was 23.3 (4.7; range, 14.0-43.1) in men
and 22.6 (4.7; range, 11.5-34.6) in women (P = .36). Mean
(SD) FFM was 47.6 (9.6; range, 14.5-69) in men and 35.7 (7.6;
range, 2.3-51.4) in women (P < .001). Body mass index and
FFM were highly correlated with each other (men, r = 0.623,
P < .001; women, r = 0.516, P < .001). Serum creatinine lev-
els were correlated with FFM (men: r = 0.336, P = .02; wom-
en: r = 0.261, P = .04) (eFigure 3 in the Supplement) but not
with BMI (men: r = 0.191, P = .18; women: r = 0.067,
P = .60). Serum albumin was not correlated with BMI (men:
r = 0.111, P = .43; women: r = 0.166, P = .18) or with FFM
(men: r = 0.231, P = .10; women: r = 0.215; P = .08). In this
cohort, serum albumin and creatinine correlated signifi-
cantly with survival in both sexes (eFigures 4 and 5 in the
Supplement).
Discussion
In our population-based series of patients diagnosed as
having ALS in the regions of Piemonte and Valle d’Aosta
from 2007 to 2011, we found that serum albumin and creati-
nine measured at time of diagnosis were markers of
outcome in both sexes, even after correction for known
prognostic factors. No other examined hematological fac-
tors were significantly related to survival at multivariable
analysis. Moreover, a dose-response effect was found for
albumin and creatinine in both sexes. These findings were
confirmed in an independent validation cohort from a ter-
tiary ALS center.
We also found that lower albumin and creatinine levels
were strongly related to worse clinical function at diagnosis
(ALSFRS-R score and FVC). Albumin levels were correlated
with indices of inflammatory state and not with nutritional
parameters. In the validation series, serum creatinine levels
(but not albumin levels) were related to patients’ FFM, indi-
cating that serum creatinine is a proxy of muscle mass.
Sensitivity and specificity values inpredicting 1-yearmor-
tality indicated that serumalbumin and creatininehaveprop-
erties similar to the best establishedprognostic factors of ALS
such as FVC, ALSFRS-R score, and age. For all these factors,
sensitivitywashigher than specificity, indicating that they re-
liably predict a survival of less than 1 year.
Albumin is a plasma-nonglycosylated protein with vari-
ous functions including transportation of several substances
such as fatty acids, bilirubin, and regulation of colloidal os-
motic pressure18 and has strong antioxidant properties.19 Al-
bumin is synthesized by the liver and its metabolism is influ-
enced by nutritional intake and inflammatory disorders.20 It
has been reported that albumin is a prognosticmarker in geri-
atric long-term care facility residents,21 individuals undergo-
ingsurgical interventions,22,23patientswithkidneydisorders,24
internal medicine patients,25 and patients diagnosed as hav-
ing cancer.26 It is unclear whether in these conditions albu-
min levels areamarkerofpatients’nutritional statusor chronic
inflammatory state, which decreases the hepatic synthesis of
albumin through the production of proinflammatory
cytokines.26,27
Table 2. Discovery CohortMultivariableModel inMen andWomena
Variable Hazard Ratio (95% CI) P Value
Men
Age, y
<50 1 [Reference]
<.001
50-59 1.49 (1.15-2.58)
60-69 2.14 (1.22-3.75)
70-79 3.08 (1.69-5.61)
≥80 4.57 (2.08-10.0)
FVC
>85 1 [Reference]
<.001
≤85 1.91 (1.33-2.73)
ALSFRS-R bulbar score
12 1 [Reference]
.001
<12 1.63 (1.23-2.15)
ALSFRS-R respiratory score
12 1 [Reference]
.004
<12 1.53 (1.15-2.05)
Creatinine, mg/dL
>0.82 1 [Reference]
.007
≤0.82 1.47 (1.11-1.95)
Albumin, g/dL
>4.3 1 [Reference]
.02
≤4.3 1.39 (1.05-1.90)
Women
Age, y
.01
<50 1 [Reference]
50-59 1.30 (1.07-2.40)
60-69 1.56 (1.15-2.86)
70-79 2.13 (1.22-4.18)
≥80 3.50 (1.53-8.00)
FVC
>0.85 1 [Reference]
.001
≤85 1.77 (1.25-2.49)
ALSFRS R bulbar score
12 1 [Reference]
.001
<12 1.75 (1.24-2.46)
Creatinine, mg/dL
>0.65 1 [Reference]
.02
≤0.65 1.49 (1.07-2.05)
Albumin, mg/dL
>4.3 1 [Reference]
.001
≤4.3 1.73 (1.25-2.39)
ALSFRS-R total score
≥39 1 [Reference]
.04
<39 1.40 (1.01-1.94)
Abbreviations: ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating
Scale–Revised; FVC, forced vital capacity.
SI conversion factors: To convert albumin to grams per liter, multiply by 10; to
convert creatinine to micromoles per liter, multiply by 76.25.
a Hematological factors were included in the Coxmodel, stratified according to
their median value. Enteral nutrition and noninvasive ventilation were
included as time-dependent variables. A secondmodel was performed
replacing ALSFRS-R total score and its subscores with their decline rates (data
not shown).
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In2 studies, serumalbumindecreased inpatientswithALS
comparedwith healthy control participants.28,29 However, to
our knowledge, this is the first study demonstrating that al-
bumin levels, evaluated at the time of diagnosis, are a strong
and independent marker of ALS outcome and strictly corre-
lated with patients’ clinical status. The lack of correlation of
serumalbuminwithBMI inboth cohorts indicates that inALS,
albumin levels are poorly influencedbynutritional status. On
the other hand, the significant correlation of serum albumin
with leukocytes, granulocytes, andESR indicates that the low-
eringof albumin levels inpatientswithALS isprobably caused
by their inflammatory state. In both our cohorts, the increase
Figure 1. Discovery Cohort Kaplan-Meier Curves
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Patients with values more than
the median of the group
Patients with values less than
the median of the group
MenA WomenB
MenC WomenD
MenE WomenF
Survival was stratified by serum creatinine levels at diagnosis. A, Men:0.82 vs
>0.82mg/dL (P = .004). B, Women:0.65 vs >0.65mg/dL (P = .004). Survival
was stratified by serum albumin levels at diagnosis. C, Men:4.3 vs >4.3 g/dL
(P < .001). D, Women:4.3 vs >4.3 g/dL (P < .001). Survival was stratified by
serum lymphocytes count at diagnosis. E, Men:1700 vs >1700 /μL (P = .04).
F, Women:1700 vs >1700 /μL (P = .02). To convert lympohcytes to ×109/L,
multiply by 0.001; albumin to grams per liter, multiply by 10; and creatinine to
micromoles per liter, multiply by 76.25.
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of leukocytes and granulocytes was significantly related to a
low ALSFRS-R respiratory subscore and reduced FVC, sug-
gesting that respiratory failure could be one of the causes of
inflammatory state in ALS.
In a previous study, chronic inflammatory statewas iden-
tified in 80 patientswith ALS inwhomwide-range C-reactive
protein, ESR, and fibrinogen levels were significantly higher
than inmatchedcontrolparticipants; theseparameters showed
a significant correlation with ALSFRS-R scores, which per-
sisted on sequential examinations.30 In line with this obser-
vation, ALSFRS-R score was correlated with ESR and neutro-
phils count.
Serum creatinine is a product of nonenzymatic catabo-
lismofcreatinephosphate inmuscles,producedata fairly con-
stant rate by the body (each day, 1%-2% of muscle creatine is
converted to creatinine),31 and is transported from muscle
through the circulation to the kidneys.32 Its levels depend on
musclemass;men tend tohave ahigher level thanwomenbe-
cause they generally have a greater muscle mass. In contrast
to serumcreatinekinase, creatinine levels arenotmodifiedby
physical activity.33
Ithasbeenshownthat creatinine levels are correlatedwith
leanbodymass inhealthy individuals34 and in adults andchil-
dren with various diseases.31,33,35 Serum creatinine has also
been found tobeapredictive factorof survival inpatientswith
spinal and bulbar muscular atrophy.36
In both our cohorts, creatinine levels, which were inde-
pendently related to ALS outcome, showed a significant cor-
relation with ALSFRS-R score and with BMI, which are pre-
dictors of ALS prognosis.37-40 Malnutrition, causing loss of
weight and, in particular, muscle mass, represents a relevant
event in the course of ALS. However, in our discovery cohort,
which includedpatients enrolledat timeofdiagnosis,BMIwas
not a prognostic factor. On the other hand, in our validation
cohort, serumcreatininewasmorestrictlycorrelatedwithFFM
thanBMI.Fat-freemass consists of all tissues that arenotbody
Figure 2. Discovery Cohort Associations
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A, Correlation between Amyotrophic Lateral Sclerosis Functional Rating
Scale–Revised (ALSFRS-R) score and serum creatinine levels (men: r = 0.165,
y = 0.006x + 0.591, P = .003; women: r = 0.256, y = 0.005x + 0.416, P < .001).
B, Correlation between forced vital capacity (FVC) and serum creatine levels
(men: r = 0.24, y = 0.002x + 0.622, P = .003; women: r = 0.151, y = 0.001x +
0.544, P < .001). C, Correlation between ALSFRS-R score and serum albumin
levels (men: r = 0.465, y = 0.033x + 2.961, P < .001; women: r = 0.324,
y = 0.019x + 3.505, P < .001). D, Correlation between FVC of predicted
percentage and serum albumin levels (men: r = 0.379, y = 0.007x + 3,633,
P < .001; women: r = 0.268, y = 0.004x + 0.3.902, P < .001). To convert
albumin to grams per liter, multiply by 10 and creatinine to micromoles per liter,
multiply by 76.25.
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fat and therefore is more representative of the loss of muscle
mass in ALS.41
We did not find any other hematological factor to be in-
dependently related to ALS outcome at multivariable analy-
sis. Oneof themost studiedhematological factors inALSwith
contrasting results is lipid status.5,6,8,29,42-44 A pivotal study5
found thathigherLDLcholesterol toHDLcholesterol ratiowas
correlatedwith a betterALSprognosis. Conversely, in our dis-
covery cohort, a lower LDL cholesterol to HDL cholesterol ra-
tio was significantly related to better survival in women but
wasnot retained inthemultivariableanalysis.Twostudieshave
shown that both patients with ALS and their familymembers
have a beneficial vascular risk profile (ie, a lower frequencyof
cardiovasculardisorders) and thatLDLcholesterol toHDLcho-
lesterol ratio is not a significant prognostic factor when ad-
justed forknownconfounders.44,45 Inaddition, cholesterol lev-
els have been found to be inversely related to respiratory
function, suggesting the increaseduseof cholesterol as an en-
ergetic nutrient in respiratory failure42; this finding is con-
firmed in eTable 5 in the Supplement.
Theprotective roleofhigh levels of serumuric acid inneu-
rodegenerative disorders is another area that has been ex-
plored following the demonstration that uric acid can have
natural antioxidant properties in humans.46,47 There are indi-
cations that high levels of serumuric acid are related to a bet-
ter prognosis in Parkinsondisease,48,49Huntingtondisease,50
multiple system atrophy,51 and mild cognitive impairment.52
In 2 small series, uric acid levelswere found to be lower in pa-
tients with ALS than in control participants and were corre-
latedwithALSFRS-R scoredecline rate7 or diseaseduration.53
In other studies, serum uric acid was independently corre-
lated with the decline of ALSFRS-R score and of FVC in both
sexes8oronly inmalepatients.43 Inbothour series, serumuric
acid was not prognostic of ALS outcome and showed no cor-
relation with clinical status in either sex.
A strength of our discovery cohort is that it is highly rep-
resentative of the general ALS population. Our cohort in-
cludes roughly90%of thepatientswhowerediagnosedashav-
ing ALS in the study period in Piemonte and Valle d’Aosta
regions.Capturedcasesdidnotdiffer for anysignificantdemo-
graphicor clinical parameters fromnoncapturedpatients.Our
validation cohort consisted of a consecutive series of patients
at different clinical stages from a tertiary center, recruited for
a study on lean bodymass; these patients had longer disease
duration andmore severe disease than those of the discovery
cohort; and as predicted from our findings, in the discovery
cohort, patients had lower serumalbumin and creatinine lev-
els, suggesting the progressive decrease of these hematologi-
cal factors during the course of the disease.
Conclusions
In this study,wehave shown that serumcreatininemeasured
at diagnosis is an independent marker of ALS outcome be-
cause it reflects the state ofmusclemass of the individual and
is correlated with both the functional declinemeasured with
ALSFRS-R score and FFM. Albumin levels are also indepen-
dently related to ALS outcome, likely representing a marker
of the inflammatory state rather than a marker of nutritional
status.Noneof theotherhematological factors examinedwere
predictive of ALS outcome.
Both creatinine and albumin are reliable and easily de-
tectable blood markers of the severity of motor dysfunction
inALS and couldbeused indefiningpatients’ prognosis at the
time of diagnosis. Longitudinal studies on the variations of
serum albumin and creatinine levels and their relationships
to clinical status will help determine whether and how these
hematological factors vary during the progression of the
disease.
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